![Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes - ScienceDirect Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253819310476-fx1.jpg)
Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes - ScienceDirect
![Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial - The Lancet Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/2001011662/2003799460/gr1.gif)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial - The Lancet
![Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome - ScienceDirect Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253815560699-gr1.jpg)
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome - ScienceDirect
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g001.jpg)